pI: 9.1394 |
Length (AA): 302 |
MW (Da): 32994 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
140 | 300 | 2pq5 (A) | 25 | 192 | 29.00 | 0.0000000000063 | 1 | 0.972613 | -1.07 |
159 | 296 | 2r0b (A) | 27 | 171 | 38.00 | 0 | 1 | 1.03825 | -1.68 |
160 | 299 | 2esb (A) | 19 | 158 | 29.00 | 0 | 1 | 0.967276 | -1.42 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_128368)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G06110 | MAPK phosphatase 2 |
Caenorhabditis elegans | CELE_Y54F10BM.13 | Protein Y54F10BM.13 |
Cryptosporidium hominis | Chro.30177 | dual specificity protein phosphatase |
Cryptosporidium parvum | cgd3_1470 | dual specificity phosphatase |
Dictyostelium discoideum | DDB_G0283417 | hypothetical protein |
Drosophila melanogaster | Dmel_CG34099 | MAP kinase-specific phosphatase |
Echinococcus granulosus | EgrG_001042600 | dual specificity protein phosphatase 19 |
Entamoeba histolytica | EHI_053090 | leucine rich repeat and phosphatase domain containing protein |
Entamoeba histolytica | EHI_110140 | dual specificity protein phosphatase, putative |
Echinococcus multilocularis | EmuJ_001042600 | dual specificity protein phosphatase 19 |
Homo sapiens | ENSG00000162999 | dual specificity phosphatase 19 |
Homo sapiens | ENSG00000198252 | serine/threonine/tyrosine interacting protein |
Leishmania braziliensis | LbrM.27.2390 | dual specificity protein phosphatase, putative |
Leishmania donovani | LdBPK_272130.1 | dual specificity protein phosphatase, putative |
Leishmania infantum | LinJ.27.2130 | dual specificity protein phosphatase, putative |
Leishmania major | LmjF.27.2210 | dual specificity protein phosphatase, putative |
Leishmania mexicana | LmxM.27.2210 | dual specificity protein phosphatase, putative |
Loa Loa (eye worm) | LOAG_06386 | hypothetical protein |
Mus musculus | ENSMUSG00000027001 | dual specificity phosphatase 19 |
Mus musculus | 56291 | serine/threonine/tyrosine interaction protein |
Onchocerca volvulus | OVOC7776 | Dual specificity protein phosphatase 19 homolog |
Plasmodium yoelii | PY00863 | hypothetical protein |
Schistosoma japonicum | Sjp_0305590 | ko:K01090 protein phosphatase [EC3.1.3.16], putative |
Schistosoma mansoni | Smp_084930 | dual specificity protein phosphatase |
Schmidtea mediterranea | mk4.000367.01 | Putative dual specificity protein phosphatase |
Trypanosoma brucei gambiense | Tbg.972.2.2900 | dual specificity protein phosphatase, putative |
Trypanosoma brucei | Tb927.2.4870 | kinetoplastid-specific dual specificity phosphatase, putative |
Trypanosoma cruzi | TcCLB.511621.190 | dual specificity protein phosphatase, putative |
Trypanosoma cruzi | TcCLB.504741.170 | dual specificity protein phosphatase, putative |
Trichomonas vaginalis | TVAG_106820 | vh3 dual specificity phosphatase, putative |
Trichomonas vaginalis | TVAG_419930 | dual specificity protein phosphatase, putative |
Trichomonas vaginalis | TVAG_323340 | vh3 dual specificity phosphatase, putative |
Trichomonas vaginalis | TVAG_160370 | vh5 dual specificity phosphatase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.2.4870 this record | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.2.4870 this record | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.2.4870 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.2.4870 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | increased (PATO:0000470) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.6
1 literature reference was collected for this gene.